Indobell Insulations Limited Announces Rs.1,014.30 Lakhs IPO to Drive Expansion and Growth

Kolkata (West Bengal) [India], January 03: Indobell Insulations Limited, a prominent manufacturer and contractor of specialized insulation products, has launched its Initial Public Offering (IPO) on the BSE SME platform. The IPO aims to raise ₹1,014.30 lakhs through the issuance of 22,05,000 equity shares, priced at ₹46 each. The issue is open from January 6 to January 8, 2025.

IPO Highlights

  • Issue Size: ₹1,014.30 lakhs
  • Price Per Share: ₹46
  • Market Lot: 3,000 shares
  • Post-IPO Dilution: 35%
  • Listing Platform: BSE SME

Utilization of Funds

The proceeds from the IPO will be directed towards:

  1. Acquiring advanced machinery to enhance production capacity.
  2. Supporting working capital requirements to streamline operations.
  3. General corporate purposes.

Business Overview

Indobell Insulations Limited specializes in Nodulated Wool, Ceramic Fibre Nodules, and Mineral Fibre Nodules, catering to diverse industries, including power, commercial, and industrial sectors. The company offers comprehensive solutions such as consultancy, engineering, fabrication, installation, and project management.

With state-of-the-art manufacturing facilities in West Bengal and Maharashtra, Indobell ensures superior quality and efficient production processes, positioning itself as a trusted partner in the insulation sector.

Impressive Financial Growth

The company has demonstrated robust financial performance, with revenue of ₹556.30 lakhs and a PAT of ₹42.39 lakhs for the half-year ending September 30, 2024. Its EBITDA margin stands at 15.17%, reflecting operational efficiency. Its net worth is ₹609.49 lakhs, ensuring strong financial stability and growth potential.

Speaking on the IPO launch, Managing Director Mr. Vijay Burman said, “This IPO marks a new chapter in our growth journey. The funds raised will enable us to strengthen our manufacturing capabilities and expand our market presence. We are committed to creating long-term value for our investors and stakeholders while driving innovation in the insulation industry.”

For more information, please visit: www.indobell.com

For Media Inquiries:

ICON PR and Media

iconprgujarat@gmail.com

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

Related Posts

One Analyst, 71,000 Investors: Why Ankit Jaiswal Built NiveshX

Bengaluru (Karnataka) [India], October 29: Your groceries arrive in 20 minutes. Biryani at midnight takes 30. Yet for most Indian investors, honest research on the stock they are about to…

CivitTDRx Enables a Digital-First Approach to Transparent TDR Transactions

New Delhi [India], October 29: SoftTech Engineers Limited, a pioneer in AECO (Architecture, Engineering, Construction & Operations) technology and e-governance solutions, has introduced CivitTDRx — a digital TDR exchange solution…

You Missed

Bollywood Actor Kamlesh Sawant Takes On India’s English-Speaking Challenge in New MySivi Ad

Bollywood Actor Kamlesh Sawant Takes On India’s English-Speaking Challenge in New MySivi Ad

One Analyst, 71,000 Investors: Why Ankit Jaiswal Built NiveshX

One Analyst, 71,000 Investors: Why Ankit Jaiswal Built NiveshX

CivitTDRx Enables a Digital-First Approach to Transparent TDR Transactions

CivitTDRx Enables a Digital-First Approach to Transparent TDR Transactions

World Book of Records (UK) Awards & Summit in Tunisia Celebrates Global Excellence with 50 Countries and Silver Jubilee of International Siddhashram Shakti Centre, UK

World Book of Records (UK) Awards & Summit in Tunisia Celebrates Global Excellence with 50 Countries and Silver Jubilee of International Siddhashram Shakti Centre, UK

Lincoln Pharmaceuticals Ltd Reports Consolidated Net Profit of Rs. 57.50 crore in H1 FY27, growth of 20.52 percent Y-o-Y

Lincoln Pharmaceuticals Ltd Reports Consolidated Net Profit of Rs. 57.50 crore in H1 FY27, growth of 20.52 percent Y-o-Y

AtHomeCare™ Trialling Integrated App to Streamline Post-Discharge Care, Reduce Readmissions

AtHomeCare™ Trialling Integrated App to Streamline Post-Discharge Care, Reduce Readmissions